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A protein has been purified from pig bone marrow which enhances the activity of exogenously added granulocyte-macrophage colony stimulating 
factor (GM-CSF) on mouse myelopoietic colony formation in vitro. The substance alone did not exhibit any colony stimulating activity. The active 
fraction was isolated from the medium of pig bone marrow suspension cultures during 20-24 h. Purification to homogeneity was then performed 
by subsequent HPLC and SDS-PAGE. The GM-CSF enhancing protein was identified as a 155 kDa glycoprotein. 
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1. INTRODUCTION 
In the present work we have investigated conditioned 
medium from bone marrow culture in order to identify 
high molecular weight substances which may be in- 
volved in the stimulation of colony formation induced 
by GM-CSF. It appears that bone marrow cells produce 
a regulatory protein (‘enhancing protein’; EnP), which 
may be a cofactor in the regulation of myelopoiesis. 
2. MATERIALS AND METHODS 
2. I, Production of serum-free conditioned medium 
Bone marrow cells were obtained from the ribs of freshly killed 
adult pigs by crushing followed by washing in standard Eagle’s mini- 
mum essential medium (Flow Lab, Glasgow, UK). About 100 ribs 
(-0.035 kg each) were used in order to obtain approximately 30 I of 
the conditioned medium. The bone crumb was mixed with 500 ml of 
medium (ratio 4: 1 v/w) in a round bottle tissue culture flask and placed 
on a heated shaker (Hereaus GmbH, Germany) for 1 h at 37”C, 
followed by separation of the bone fragments by filtration through 0.5 
mm pore-size multilayered nylon mesh. The filtrate (consisting ap- 
proximately 50% of fatty substances) was centrifuged at 200 x g for 
10 min and the deposited cells washed twice: first in standard Eagle’s 
medium, followed by medium 199 (Flow Lab. Glasgow. UK). The 
cells were counted, tested for viability by the Trypan blue exclusion 
test. and then seeded into sterile glass culture flasks at a concentration 
of 2 x lo7 cell/ml in serum-free medium 199 contained 20 mM of 
glutamine, HEPES 0.01 M, penicillin 100 U/ml. The cell suspension 
was incubated at 37°C and 5% CO: in humidified air. Cell viability 
during the period of incubation was more than 95%. 
After 20-24 h of incubation, the conditioned medium was collected 
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by centrifugation at 10,000 x g for 30 min and then concentrated 10 
times by ultrafiltration using an Amicon LP-1A pump fitted with 
HIP3 hollow fibre filters (cut off 3 kDa) at 10 mllmin flow rate. The 
subsequent purification steps (except HPLC) were performed in a cold 
room below 4°C. 
2.2. Geljltrotion 
Ten ml of the conditioned medium concentrate was applied to a 
column (2.6 x 100 cm, LKB, Sweden) fitted with Toyopearl HW-55 
(Toyo Soda Manufacturing Co., Japan) equilibrated with double- 
distilled water. A Multiperpex 2115 peristaltic pump, Uvicord SII 
monitor, equipped with a 214 nm absorbance filter was used together 
with an Ultrarac 7000 automatic fraction collector (all from LKB 
Pharmacia. Uppsala, Sweden). The flow rate was 100 ml/h. The sam- 
ples were washed through the column with approximately 600 ml of 
the eluent and the active fraction was eluted in the void volume. 
Thereafter the active fractions were pooled and freeze dried. This 
purification protocol resulted in -0.1% yield of the active fraction 
from the content of UV-absorbing material loaded onto a column. 
2.3. High pe~formunce liquid chromatography (HPLC) 
Using an appropriate column, HPLC was performed at room tem- 
perature using a Spectra-Physics model SP8000B liquid chromato- 
graph fitted with a 1 ml sample loop. The samples emerging from the 
column were monitored with a LDC Spectromonitor III at 226 nm 
wavelength, and the protein content was assessed by comparing the 
absorption of a known amount of IgG Fab’ fragment at the same 
wavelength. A lyophilired sample of the active fraction from the 
Toyopearl column was dissolved in normal saline (I mg in 0.2 ml) and 
then chromatographed on a TSK 3000SW size exclusion column 
(60 x0.75 cm internal diameter, Toyo Soda Manufacturing Co., 
Japan). The mobile phase consisted of aqueous sodium chloride (0.9%, 
w/v), pH 5.6, at a flow rate of 1 ml/min at ambient temperature, and 
the proteins eluted from the column were detected by UV absorption. 
One ml fractions were collected automatically into propylene tubes 
containing 100 ~1 of 0.2% (w/v) Tween solution (Fluka AG, Switzer- 
land). Aliquots of 10 ~1 were tested for biological activity. 
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2.4. Rechrornatography on the PHPLC column 
The fractions containing enriched material were collected manually 
and rechromatographed in order to avoid impurities. The total volume 
applied was not more than 0.5 ml. SDS-PAGE under reducing condi- 
tions (in presence of 2-mercaptoethanol) was used to assess the purity 
of the fractions. 
2.5. SDS-PAGE and protein blotting 
SDS-PAGE (12.5% acrylamide, w/v) was performed as described 
previously [I]. Each sample was boiled for 5 min in the starting buffer 
containing 2-mercaptoethanol and 335% SDS before use. Apparent 
molecular weight was estimated by comparison with protein stan- 
dards. The gels were stained with Coomassie blue R-250 or with 
Schiff’s reagent [2,3]. The protein separated by SDS-PAGE were sub- 
sequently blotted onto nitrocellulose paper using a Trans Blot unit 
(Bio-Rad Laboratories, CA, USA) under conditions described previ- 
ously [4] and stained with Amido black dye [5]. 
2.6. Biological testing 
Assay was performed in semisolid agar culture using 75,000 C57Bl 
mouse bone marrow cells per 35 mm plate [6]. The proteins to be tested 
were added with or without mouse recombinant GM-CSF (Amgen 
Corp., USA), to the petri dishes and mixed with the cell suspension. 
All samples were sterilized by filtration (0.22 pm Acrodisc, Gelman 
Sci., USA). Colony formation (~50 cells) was determined after 7 days 
of incubation using an inverted microscope. 
3. RESULTS 
The conditioned medium (CM) obtained from bone 
marrow culture was filtered through a 0.45 ,um sterile 
filter unit (Millipore Corp., USA) and then concen- 
trated 100 times by ultrafiltration. This procedure was 
performed in two steps. First, a lo-fold concentration 
was achieved by desalting with double-distilled water in 
the same equipment overnight, with the procedure being 
repeated in the following day. No aggregation or lipid- 
like formation was found in the concentrate. During 
this procedure, a major part of the constituents with 
molecular weights lower than 3000 Da was discarded. 
About 30 1 of the primary CM were processed in this 
manner to obtain enough material for further purifica- 
tion. 
3.1. Gel chromatography 
In the chromatographic profile five peaks were regis- 
tered in CM concentrate by two different absorption 
wavelengths (Fig. 1). Medium which had not been in 
Fig. 1. Gel filtration chromatography of the conditioned medium on 
Toyopearl HW-55 column. Constant line: conditioned medium pro- 
file. Dashed line: culture medium (control sample) profile. 
contact with the cells was analyzed for control purposes 
and this control profile is also presented in Fig. 1. A 
difference between the CM control sample was found 
only in the first fraction (void volume). Since double- 
distilled water was used as an eluent on the Toyopearl 
HW-55 column the separation pattern was not a result 
of a size exclusion effect only. This is because 
Toyopearl-type matrix gels show a slight anion ex- 
change effect which appears at low ionic strength. In 
our experiments, the anion exchange effect was utilized 
to eliminate unwanted components from the incubation 
medium. Fraction 1 was pooled from about 20 chro- 
matographic runs, frozen and lyophilized. The presence 
of an amino group- as well as carbohydrate-containing 
substances was shown by staining tests with ninhydrin 
and diphenylamine reactions [7]. 
3.2. Biological activity of’ CM fraction 
The CM fraction obtained by gel chromatography on 
Toyopearl HW-55 was assayed for possible colony 
stimulating activity (CSA). No CSA in semisolid agar 
culture of mouse bone marrow cells was observed. 
When optimal (10 ng) or suboptimal (1 ng) doses of 
GM-CSF were added together with the CM fraction, 
enhancement of the GM-CSF activity was observed 
(Fig. 2). The CM fraction did not affect colony mor- 
phology and the ratio of granulocyte to macrophage 
colonies was not changed (data not presented). 
3.3. PuriJcution of CM fraction 
The active fraction was subjected to SDS-PAGE on 
12.5% gels and stained by Coomassie blue R-250 (Fig. 
3). The SDS-PAGE showed that the proteins in the CM 
fraction were well resolved according to molecular 
weight. High performance size-exclusion liquid chroma- 
tography was chosen as the purification method to 
maintain the conditions favourable to flexible mole- 
cules, and proved to be effective. The fraction from the 
Toyopearl HW-55 column containing stimulating activ- 
Fig. 2. Stimulation of the colony formation in GM-CSF activated 
mouse bone marrow cells by CM fraction. Matched bar: I ng of 
GM-CSF alone. Open bar: IO ng of GM-CSF alone. o: CM frac- 
tion + IO ng of GM-CSF. A: CM fraction + 1 ng of GM-CSF. 
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Fig. 3. SDS-PAGE analysis of the different fractions. Track I, F2 
fraction: Track II, F3 fraction; Track III, CM fraction; Track IV, FI 
fraction. 
ity was lyophilized and chromatographed on a TSK 
3000SW column. Each 1 ml fraction was collected, fil- 
tered through a sterile 0.22 pm filter and tested for 
biological activity. The active substances were eluted 
between 14 and 17 min (F2) as shown on Fig. 4. No 
other fractions were found to stimulate the response to 
GM-CSF so dramatically. Each of the first four frac- 
tions was collected separately and analyzed by SDS- 
PAGE (Fig. 3) and no proteins were detected in Fl 
Fig. 4. Size exclusion chromatography of CM fraction on TSK 
3000SW column. Shaded area: biological effect of the corresponding 
fractions. 
even after concentration of this fraction. The molecular 
weight of F2 was found to be 155 kDa. 
3.4. Rechromatogruphy of F2 
Before rechromatography F2 was concentrated 10 
times by lyophilization and dialyzed against normal sa- 
line, pH 5.6. Rechromatography of F2 revealed five 
fractions. One of them (about 80% of the subjected 
material according to UV absorbance) eluted between 
15 and 17 min and showed biological activity (Fig. 5). 
The optima1 dose of active fraction was 0.1-1.0 lug of 
protein per 35 mm plate, i.e. 1 ml culture medium. 
In spite of a low protein concentration fraction 2a 
was the most pure and contained only a 155 kDa com- 
ponent and lacked the lower molecular weight impuri- 
ties presented in F2. 
4. DISCUSSION 
Although the existence of the colony stimulating fac- 
tors and other cytokines as potent stimulators of both 
hemopoiesis and leukocyte functions has been well es- 
tablished for several years (see e.g. [S-lo]) the more 
complex underlying regulatory mechanisms have re- 
cently been documented. Firstly, rather complex inter- 
actions between these factors and the relative expression 
of their target cell receptors have been found. Secondly, 
it has been realized that hemopoiesis is a balance be- 
tween stimulatory and inhibitory factors both of high 
[1 11 and low molecular weight [12,13]. 
It is also known that bone marrow cells in long term 
culture, and specifically macrophages secrete a factor 
which enhances the stimulatory effect of GM-CSF 
[14,15]. Recently, this factor has been identified as a 
glycoprotein with molecular weight 74 kDa which 
seems to be a unique cytokine different from other he- 
matopoietic enhancing factors [ 161. Using the PTH-de- 
rivative technique and an automatic protein sequencer, 
we have identified the first ten amino acids at the N- 
terminal end of our 155 kDa protein as a unique se- 
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Fig. 5. Rechromatography of F2 fractions on TSK 3000SW column. 
Shaded area: biological effect of the corresponding fractions. 
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quence (the authors, manuscript in preparation). In ad- 
dition to this, the differing molecular weight from the 
other described protein suggests that these are two dif- 
ferent proteins with a similar enhancing activity. To 
what extent our protein is specific for hemopoiesis as 
appears to be the case for the other one [16], is so far 
not known. 
It is earlier known that serum albumin may bind 
growth factors. In addition, BSA contains an activity 
which is necessary for the stimulatory effect of IL-3 [17]. 
However, this mechanism cannot explain our described 
enhancing activity. Since the EnP was found in pig bone 
marrow and acted on mouse cells, the factor does not 
seem to be species specific. 
In short-term bone marrow suspension culture, both 
immunostimulating and immunosuppressing molecules 
[ 1 S-201 as well as hemoregulatory peptides of low mo- 
lecular weight [21] may be present. In line with this, also 
the hemoregulatory peptide dimer may act as a GM- 
CSF enhancer [21]. Thus, both oligopeptides and pro- 
teins may strongly modify myelopoiesis. 
We conclude that EnP is a novel glycoprotein which 
may have a modifying effect on myelopoietic activity in 
concert with hemopoietic growth factors and other reg- 
ulatory molecules. 
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